Form 4: SAB Biotherapeutics Director Receives Stock Option Grants

Christine E. Hamilton, a director of SAB Biotherapeutics, received multiple stock option grants on July 15, 2024, as part of her compensation and for her spouse's advisory role.

Summary

• Christine E. Hamilton, a director at SAB Biotherapeutics, Inc., received several stock option grants on July 15, 2024.
• These grants include an annual grant for her role as a board member and one-time grants for both her and her spouse, who serves as an advisor to the board.
• The options have exercise prices of $2.90 and $5.40.
• Some options vest in installments over two or three years, while others are fully vested.
• The grants were made under the company's 2021 Omnibus Equity Incentive Plan, as amended.

Sentiment

Score: 7

Explanation: The document reflects standard compensation practices, indicating stability and alignment of interests. The sentiment is neutral to slightly positive.

Positives

• The grants align the director's and advisor's interests with the company's long-term performance.
• The vesting schedules encourage continued service and contribution to the company.

Future Outlook

The document does not contain specific forward-looking statements, but the equity grants suggest an expectation of continued service and contribution from the director and advisor.

Industry Context

Stock option grants are a common form of compensation for directors and advisors in publicly traded companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Stock option grants to board members are a standard practice across the biotechnology industry.
• The vesting schedules (two to three years) are typical for such grants, encouraging long-term commitment.
• Comparing the size of the grants to those of directors at similar-sized biotech companies (e.g., those with market caps between $50 million and $200 million) would provide a benchmark for assessing the competitiveness of SAB Biotherapeutics' compensation practices.

Related Party Transactions

• The grant of stock options to the Reporting Person's spouse, who serves as an advisor to the Board, constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the grants positively as aligning the interests of the director and advisor with the company's success.
• Employees may see the grants as a sign of the company's commitment to its leadership.

Key Dates